首页> 中国专利> 人AD7C-NTP抗原决定簇多肽、抗体及其在诊断试剂盒上的应用

人AD7C-NTP抗原决定簇多肽、抗体及其在诊断试剂盒上的应用

页面导航

摘要
著录项
法律信息
相似文献

摘要

本发明为一种人AD7C-NTP抗原决定簇多肽、抗体及其在诊断试剂盒上的应用。本发明的AD7C-NTP抗原决定簇多肽，为序列表SEQ ID NO.1至SEQ ID NO.6所述的多肽片段之一。本发明的AD7C-NTP抗体，是由本发明的任一种AD7C-NTP抗原决定簇多肽制备而成。本发明的AD7C-NTP抗体可应用于制备AD7C-NTP体外诊断试剂盒。

著录项

公开/公告号CN101215323B

专利类型发明专利
公开/公告日2011-11-30

原文格式PDF
申请/专利权人首都医科大学宣武医院;深圳市安群生物工程有限公司;
展开▼

申请/专利号CN200710125584.5
发明设计人盛树力;王蓉;姬志娟;朱建安;
展开▼

申请日2007-12-28
分类号
代理机构北京天昊联合知识产权代理有限公司;
代理人丁业平
地址 100053 北京市宣武区长椿街45号宣武医院
入库时间 2022-08-23 09:08:22

法律信息

法律状态公告日

法律状态信息

法律状态
2011-11-30

授权

授权
2008-09-03

实质审查的生效

实质审查的生效
2008-07-09

公开

公开

相似文献

专利
中文文献
外文文献

1. 人AD7C-NTP抗原决定簇多肽、抗体及其在诊断试剂盒上的应用 [P] . 中国专利： CN101215323B . 2011.11.30
2. 人肿瘤M2型丙酮酸激酶抗原决定簇多肽、抗体及其在诊断试剂盒上的应用 [P] . 中国专利： CN100554278C . 2009.10.28
3. isolated polynucleotide, expression cassette, host cell, isolated polypeptide, non-human transgenic animal that has been altered to express an alkali resistant mutant polypeptide, an antibody that specifically binds to an alkali resistant mutant polypeptide, a mutation detection kit alk inhibitor resistance in a biological sample, and methods for evaluating a biological sample for an alk inhibitor resistance mutation to diagnose cancer that is resistant to or likely to develop resistance to at least one alkaline inhibitor. small alk molecule kinase, to evaluate a biological sample for an alk inhibitor resistance mutation, to diagnose cancer that is resistant to or likely to develop resistance to pf-02341066 in a patient, to specifically reduce expression of an alk-resistant mutant to treat cancer associated with activating aberrant loop capacity that is resistant to at least one small molecule alk kinase inhibitor treating an aberrant cancer that is resistant to pf-02341066, identifyin [P] . BR112012026239A2 . 2018-06-26

机译：分离的多核苷酸，表达盒，宿主细胞，分离的多肽，已被改变以表达耐碱突变体多肽的非人类转基因动物，与耐碱突变体多肽特异性结合的抗体，突变检测试剂盒生物样品，以及用于评估生物样品中是否存在对烷基抑制剂的抗性突变以诊断对至少一种碱性抑制剂有抗药性或可能发展出抗药性的癌症的方法。小分子激酶，用于评估生物学样品中是否具有抑制碱性磷酸酶抑制剂的突变，以诊断对患者具有抗药性或可能对pf-02341066产生抗药性的癌症，从而特异性降低抗癌突变体的表达以治疗癌症与激活抗至少一种小分子烷基激酶抑制剂的异常环路能力有关，该抑制剂治疗对pf-02341066有抵抗力的异常癌症
4. Polinucleotu00eddeo insulated tape of expression, host cell, isolated transgenic non-human animal polypeptide, which has been modified to express a polypeptide mutant with resistance to ALK, antibody that binds specifically to a polypeptide mutant with resistance to ALK, kit p For detection of a mutation with resistance to ALK inhibitor in a biological sample, and,Methods for evaluating a biological sample as a mutation with resistance to ALK inhibitor, for diagnosing a cancer that is resistant to or is likely to develop resistance to at least one inhibitor of kinase small molecule ALK, to evaluate a biological sample that Anto a mutation with resistance to ALK inhibitor.For diagnosing a cancer that is resistant to or is likely to develop resistance to at least one inhibitor of kinase small molecule ALK, to assess the biological sample as a mutation with resistance to ALK inhibitor, a cancer that is resistant to dianosticar Or is likely to develop resistance to PF - 02341066 in a pati [P] . BR112012026239A2 . 2016-11-29

机译：修饰的多聚核苷酸绝缘带，宿主细胞，分离的转基因非人类动物多肽，经过修饰以表达对ALK具有抗性的多肽突变体，与对ALK具有抗性的多肽突变体特异性结合的抗体，试剂盒p用于检测生物样品中对ALK抑制剂具有抗性的突变，以及用于评估生物样品为对ALK抑制剂具有抗性的突变的方法，用于诊断对至少一种对ALK抑制剂具有抗性或可能发展出抗性的癌症激酶小分子ALK，以评估Anto对ALK抑制剂具有抗性的突变的生物样品。用于诊断对至少一种激酶小分子ALK抑制剂具有抗药性或可能产生抗性的癌症，以评估该生物样品作为对ALK抑制剂有抗性的突变，即对狄诺司他抗性或可能对PF产生抗药性的癌症-02341066
5. monoclonal antibody, light chain and heavy chain variable regions, isolated cdr, polynucleotide, therapeutic composition, methods for treating disease and disorder, for producing an antibody, for treating or alleviating the effects of disease and disorder, for reducing plaque burden in an individual's brain, to reduce the amount of plaque in an individual's brain, to decrease the total amount of soluble spruce in an individual's brain, to retain or increase an individual's cognitive memory capacity, to diagnose from or to diagnose a predisposition to an amyloid-associated disease or condition in a patient, to determine the extent of amyloidogenic plaque burden in an individual's tissue, to monitor minimal residual disease in an individual, and to predict an individual's responsiveness, cell line , test kit, epitope fir [P] . BRPI0812484A2 . 2018-06-05

机译：单克隆抗体，轻链和重链可变区，分离的cdr，多核苷酸，治疗组合物，用于治疗疾病和病症的方法，用于生产抗体的抗体，用于治疗或减轻疾病和病症的影响，用于减轻个体大脑斑块负担的方法，以减少个体大脑中的斑块数量，减少个体大脑中的可溶性云杉总量，保持或增加个体的认知记忆能力，诊断或诊断淀粉样蛋白相关疾病的易感性，或患者的身体状况，确定个体组织中淀粉样蛋白斑块负担的程度，监测个体中的最小残留疾病并预测个体的反应能力，细胞系，检测试剂盒，抗原决定簇